|1.||Koutcher, Jason A: 2 articles (02/2005 - 10/2003)|
|2.||Spees, William M: 2 articles (02/2005 - 10/2003)|
|3.||Yang, Guangli: 2 articles (02/2005 - 10/2003)|
|4.||Gade, Terence P F: 1 article (02/2005)|
|5.||Tong, William P: 1 article (02/2005)|
|6.||Bornmann, William G: 1 article (02/2005)|
|7.||Gorlick, Richard: 1 article (02/2005)|
|8.||Veach, Darren: 1 article (10/2003)|
|9.||Bornmann, William: 1 article (10/2003)|
|10.||Rubio, Maria Belen: 1 article (10/2003)|
09/01/1984 - "We concluded that either F or MTX-F produced significant improvement of nephrotoxic nephritis due to inhibition of autologous antibody production."
09/01/1984 - "To evaluate the effect of 5-fluorouracil (F) and methotrexate-5-fluorouracil association (MTX-F) on nephrotoxic nephritis, seven groups of 10 rats were inoculated with anti-rat glomerular basement membrane serum (AGBMS); five groups were treated with different doses of F, beginning on the 2nd or the 6th day, one group with MTX-F beginning on the 2nd day and one group (control) with distilled water. "
02/15/2005 - "A statistically significant linear correlation between tumor tissue concentrations of FMTX at these late time points and therapeutic response in the days/weeks post-treatment is shown (R = 0.81, F = 9.27, P < 0.001). "
02/15/2005 - "The three tumor models show differences in both the peak concentrations of tumor FMTX and the dynamics of uptake/retention. "
02/15/2005 - "The pharmacokinetics of tumor uptake/washout of FMTX were monitored via in vivo (19)F magnetic resonance spectroscopy (pulse/acquire with surface coil localization) following an i.v. bolus injection. "
10/01/2003 - "While the focus of this report is the synthetic technique of FMTX, it is also demonstrated that tumor accumulation of the labeled compound in vivo can be observed via 19F magnetic resonance spectroscopy (MRS) in a human tumor xenograft model."
02/15/2005 - "Interestingly, a 400 mg/kg i.v. bolus injection of FMTX is a more potent cytotoxic agent in vivo against methotrexate-sensitive tumors than is the parent compound (P = 0.011). "
02/01/2000 - "The results of the in vitro and in vivo studies have shown: (1) a lower in vitro cytotoxicity of the F-MTX conjugate as compared with MTX alone; (2) a significantly higher in vivo antitumor activity of the F-MTX conjugate in mice with P388 leukemia as compared with MTX alone; (3) a significantly increased in vivo lethal toxicity of F-MTX as compared with MTX. "
09/01/1984 - "The group treated with F (1.3 mg/100 g body weight) developed a severe glomerulonephritis similar to the control group; (b) the groups treated with F (2.0 mg/100 g body weight) or with MTX-F showed progressively lower proteinuria, less severe histological changes and less intense fluorescence due to autologous antibodies. "
|1.||fluoresceinated methotrexate (FMTX)
|3.||Glutamates (Glutamate, Potassium)
|5.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|1.||Heterologous Transplantation (Xenotransplantation)